Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

Abstract

SummaryBackgroundBased on previous findings, we hypothesised that radiotherapy to the prostate would improve overall survival in men with metastatic prostate cancer, and that the benefit would be greatest in patients with a low metastatic burden. We aimed to compare standard of care for metastatic prostate cancer, with and without radiotherapy.MethodsWe did a randomised controlled phase 3 trial at 117 hospitals in Switzerland and the UK. Eligible patients had newly diagnosed metastatic prostate cancer. We randomly allocated patients open-label in a 1:1 ratio to standard of care (control group) or standard of care and radiotherapy (radiotherapy group). Randomisation was stratified by hospital, age at randomisation, nodal involvement, WHO performance status, planned androgen deprivation therapy, planned docetaxel use (from December, 2015), and regular aspirin or non-steroidal anti-inflammatory drug use. Standard of care was lifelong androgen deprivation therapy, with up-front docetaxel permitted from December, 2015. Men allocated radiotherapy received either a daily (55 Gy in 20 fractions over 4 weeks) or weekly (36 Gy in six fractions over 6 weeks) schedule that was nominated before randomisation. The primary outcome was overall survival, measured as the number of deaths; this analysis had 90% power with a one-sided α of 2·5% for a hazard ratio (HR) of 0·75. Secondary outcomes were failure-free survival, progression-free survival, metastatic progression-free survival, prostate cancer-specific survival, and symptomatic local event-free survival. Analyses used Cox proportional hazards and flexible parametric models, adjusted for stratification factors. The primary outcome analysis was by intention to treat. Two prespecified subgroup analyses tested the effects of prostate radiotherapy by baseline metastatic burden and radiotherapy schedule. This trial is registered with ClinicalTrials.gov, number NCT00268476.FindingsBetween Jan 22, 2013, and Sept 2, 2016, 2061 men underwent randomisation, 1029 were allocated the control and 1032 radiotherapy. Allocated groups were balanced, with a median age of 68 years (IQR 63–73) and median amount of prostate-specific antigen of 97 ng/mL (33–315). 367 (18%) patients received early docetaxel. 1082 (52%) participants nominated the daily radiotherapy schedule before randomisation and 979 (48%) the weekly schedule. 819 (40%) men had a low metastatic burden, 1120 (54%) had a high metastatic burden, and the metastatic burden was unknown for 122 (6%). Radiotherapy improved failure-free survival (HR 0·76, 95% CI 0·68–0·84; p<0·0001) but not overall survival (0·92, 0·80–1·06; p=0·266). Radiotherapy was well tolerated, with 48 (5%) adverse events (Radiation Therapy Oncology Group grade 3–4) reported during radiotherapy and 37 (4%) after radiotherapy. The proportion reporting at least one severe adverse event (Common Terminology Criteria for Adverse Events grade 3 or worse) was similar by treatment group in the safety population (398 [38%] with control and 380 [39%] with radiotherapy).Interp...

Long‐term outcomes of combining prostate brachytherapy and metastasis‐directed radiotherapy in newly diagnosed oligometastatic prostate cancer: A retrospective cohort study

“…Although our PDRT could not completely prevent urinary obstruction, several retrospective studies proposed that definitive prostate‐directed therapy reduces the risk of urinary obstruction when compared to ADT alone . Recently, Parker et al evaluated whether radiotherapy for the prostate would improve symptomatic local events in newly diagnosed mPCa patients. This trial (STAMPEDE trial) did not support the benefits for local prostate therapy to prevent newly diagnosed mPCa patients from developing symptomatic local events such as the need for new urinary catheterization, ureteric stents and transurethral resection of prostate.…”

“…Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial compared standard of care and radiotherapy for the prostate versus standard of care for overall survival in newly diagnosed mPCa patients . This randomized phase 3 trial showed that radiotherapy for the prostate did not improve overall survival for unselected patients (HR 0.92; 95%CI: 0.80‐1.06), whereas prostate radiotherapy did improve overall survival in patients with a low metastatic burden (HR 0.68; 95%CI: 0.52‐0.90).…”

Quality of life after external beam radiotherapy for localized prostate cancer: Comparison with other modalities

“…The use of EBRT in prostate cancer patients with metastases has historically been limited to treatment with palliative intent. Several studies have proposed that radiotherapy to the prostate would improve the overall survival of patients with metastatic prostate cancer . These data are expected to change the standard of practice, as it is anticipated that patients will be offered the combination of systemic therapy and local radiotherapy, in particular, for patients with low‐volume oligometastatic prostate cancer.…”

Metastatic castration‐sensitive prostate cancer: Abiraterone, docetaxel, or…

“…In patients with disseminated mHSPC, the majority of available data have been derived from retrospective analyses, but the results from 2 prospective studies recently were presented …”